A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/522 (2006.01) A61K 31/42 (2006.01) A61K 31/4709 (2006.01) A61K 31/498 (2006.01) A61K 31/519 (2006.01) A61K 31/53 (2006.01)
Patent
CA 2626020
The invention relates to antagonists of the adenosine A2A receptor, which can be used for the preparation of medicaments for auricular fibrillation in mammals, including humans. It has been found that the A2A adenosine receptor is present in human auricular cardiomyocytes and involved in the basic pathological mechanisms of auricular fibrillation. The use of A2A antagonists is advantageous over other known agents in that A2A antagonists are directed specifically to patients with auricular fibrillation.
Les antagonistes du récepteur d'adénosine A2A selon l'invention sont utiles dans la préparation de médicaments contre la fibrillation auriculaire chez les mammifères, y compris chez l'homme. On a découvert que le récepteur d'adénosine A2a est présent dans les cardiomyocytes auriculaires humains et qu'il participe aux mécanismes pathologiques fondamentaux de la fibrillation auriculaire. Il est particulièrement avantageux d'utiliser des antagonistes A2A plutôt que d'autres agents déjà connus dans la technique car ils s'adressent spécifiquement à des patients atteints d'une fibrillation auriculaire.
Cinca Cuscullola Joan
Ciruela Alferez Francisco
Franco Fernandez Rafael
Hove-Madsen Leif
Lluis Biset Carmen
Perry + Currier
Proyecto de Biomedicina Cima S.l.
LandOfFree
Compounds for the treatment of atrial fibrillation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of atrial fibrillation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of atrial fibrillation will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1625942